CUE-102 in Recurrent Glioblastoma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorDavid Reardon, MD
About this trial
The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM).
The name of the study drug involved in this study is:
-CUE-102 (a type of fusion protein)
Eligibility criteria
Qualifiers
Have HLA-A*0201 genotype as determined by genomic testing performed locally;
Have histologically confirmed World Health Organization (WHO) Grade 4 glioblastoma, other WHO grade 4 malignant glioma or molecular GBM (based on the 2021 WHO Classification) at first recurrence. Patients with gliosarcoma are NOT eligible;
Be willing and able to provide written informed consent/assent for the trial;
Be ≥ 18 years of age on day of signing informed consent;
Disqualifiers
Received any therapy for tumor recurrence other than surgery;
More than one episode of recurrent or progressive tumor;
Is currently participating or plans to participate in another study of an investigational agent or using an investigational device.
Tumor primarily localized to the brainstem or spinal cord;
Trial design
Treatments tested in this trial
- CUE-102
Treatment groups
18 Participants
are divided into 1 treatment groupSponsors and collaborators
David Reardon, MD
Lead sponsor
Dana-Farber Cancer Institute
Sponsor institution
Cue Biopharma
Collaborator
Source ClinicalTrials.gov